Moleculin Biotech Inc (NASDAQ:MBRX) shares, rose in value on Thursday, July 10, with the stock price down by -6.64% to the previous day’s close as strong demand from buyers drove the stock to $0.53.
Actively observing the price movement in the last trading, the stock closed the session at $0.57, falling within a range of $0.512 and $0.57. The value of beta (5-year monthly) was 1.565. Referring to stock’s 52-week performance, its high was $4.71, and the low was $0.25. On the whole, MBRX has fluctuated by -20.30% over the past month.
With the market capitalization of Moleculin Biotech Inc currently standing at about $12.86 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-13.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that MBRX’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of MBRX currently trading nearly 18.17% and -27.41% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 50.18, while the 7-day volatility ratio is showing 25.36% which for the 30-day chart, stands at 16.61%. Furthermore, Moleculin Biotech Inc (MBRX)’s beta value is 1.29.
A comparison of Moleculin Biotech Inc (MBRX) with its peers suggests the former has fared considerably weaker in the market. MBRX showed an intraday change of -6.64% in last session, and over the past year, it shrunk by -68.59%%.
Data on historical trading for Moleculin Biotech Inc (NASDAQ:MBRX) indicates that the trading volumes over the past 10 days have averaged 18.05 and over the past 3 months, they’ve averaged 4.21 million. According to company’s latest data on outstanding shares, there are 24.10 million shares outstanding.
Nearly 8.74% of Moleculin Biotech Inc’s shares belong to company insiders and institutional investors own 6.13% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 1.93 million shares as on 2025-06-13, resulting in a short ratio of 2.21. According to the data, the short interest in Moleculin Biotech Inc (MBRX) stood at 1379.00 of shares outstanding as of 2025-06-13; the number of short shares registered in 2025-05-15 reached 0.98 million. The stock has fallen by -84.04% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the MBRX stock heading into the next quarter.
